Overall GENE gets a fundamental rating of 1 out of 10. We evaluated GENE against 58 industry peers in the Life Sciences Tools & Services industry. GENE has a bad profitability rating. Also its financial health evaluation is rather negative. GENE does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year GENE has reported negative net income.
In the past year GENE has reported a negative cash flow from operations.
GENE had negative earnings in each of the past 5 years.
In the past 5 years GENE always reported negative operating cash flow.

1.2 Ratios

GENE has a worse Return On Assets (-194.25%) than 98.21% of its industry peers.
With a Return On Equity value of -656.53%, GENE is not doing good in the industry: 92.86% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-194.25%
ROE	-656.53%
ROIC	N/A

ROA(3y)-102.54%

ROA(5y)-75.74%

ROE(3y)-268.4%

ROE(5y)-176.61%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

GENE has a Gross Margin (50.94%) which is comparable to the rest of the industry.
GENE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	50.94%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GENE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GENE has more shares outstanding
The number of shares outstanding for GENE has been reduced compared to 5 years ago.
GENE has a worse debt/assets ratio than last year.

2.2 Solvency

GENE has an Altman-Z score of -40.90. This is a bad value and indicates that GENE is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of GENE (-40.90) is worse than 96.43% of its industry peers.
GENE has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
GENE has a Debt to Equity ratio of 0.36. This is comparable to the rest of the industry: GENE outperforms 46.43% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.36
Debt/FCF	N/A
Altman-Z	-40.9

ROIC/WACCN/A

WACC10.02%

2.3 Liquidity

A Current Ratio of 0.88 indicates that GENE may have some problems paying its short term obligations.
GENE's Current ratio of 0.88 is on the low side compared to the rest of the industry. GENE is outperformed by 91.07% of its industry peers.
GENE has a Quick Ratio of 0.88. This is a bad value and indicates that GENE is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.83, GENE is not doing good in the industry: 87.50% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.88
Quick Ratio	0.83

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

GENE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.74%, which is quite good.
GENE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -11.76%.
Measured over the past years, GENE shows a very strong growth in Revenue. The Revenue has been growing by 213.18% on average per year.

EPS 1Y (TTM)19.74%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%34.06%

Revenue 1Y (TTM)-11.76%

Revenue growth 3Y299.13%

Revenue growth 5Y213.18%

Sales Q2Q%-18.23%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.